Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.
If approved, Itvisma (intrathecal onasemnogene abeparvovec) will be first and only gene replacement therapy for children two ...
Failing to adopt a more inclusive concept of brain health represents a massive loss of human potential,” write Husseini K.
If approved, Itvisma (intrathecal onasemnogene?abeparvovec) will be first and only gene replacement therapy for children two years and older, teens and adults with SMA in the European UnionItvisma dem ...
Click here for more articles by Kormedi.com. Looking radiant and refreshed on a spring shopping spree, former rhythmic ...
Scientists are constantly searching for better ways to treat serious brain diseases, especially those that worsen over time.
End-of-Phase 2 meeting with FDA remains on track for mid-2026 – MELBOURNE, Australia and SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or ...
Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...
The immune system is the frontline protection against infection, continually searching for and destroying unknown pathogens.
An inherited form of blindness directly comparable to a common inherited optic nerve disease in humans has been discovered in ...
An inherited form of blindness directly comparable to a common inherited optic nerve disease in humans has been discovered in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results